TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35154390

Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES) for 10 minutes, 3 consecutive days in addition to Standard Logopaedic Therapy (SLT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Logopaedic Therapy (SLT) alone
Number of subjects: 20
Study: 35154704

Group type: EXPERIMENTAL
Intervention: Standard systemic treatment for mCRC
Number of subjects: 47
Study: 35154830

Group type: EXPERIMENTAL
Intervention: MRI-based treatment plans
Number of subjects: 15

Group type: COMPARATOR
Intervention: CT-based treatment plans
Number of subjects: 15
Study: 35155529

Group type: EXPERIMENTAL
Intervention: Total and boiled potatoes intake
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: Potato consumption
Number of subjects: 3401

Group type: EXPERIMENTAL
Intervention: French fries consumption
Number of subjects: 3401
Study: 35155592

Group type: EXPERIMENTAL
Intervention: Two-dimensional speckle tracking echocardiography (2D STE) combined with multiple circulating biomarkers and accurate heart dosimetry
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Follow-up at 5-time points (baseline; after completion of RT; 2, 6, and 12 months after RT)
Number of subjects: 104
Study: 35155599

Group type: EXPERIMENTAL
Intervention: Tolvaptan add-on therapy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Loop diuretic treatment
Number of subjects: 128
Study: 35155707

Group type: EXPERIMENTAL
Intervention: Bridge-Enhanced ACL Restoration (BEAR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Autograft ACL Reconstruction (ACLR)
Number of subjects: 100
Study: 35155859

Group type: EXPERIMENTAL
Intervention: IONIS-FXI, 300 mg open-label dose
Number of subjects: 49
Study: 35155863

Group type: EXPERIMENTAL
Intervention: HCV D-RNA-positive/R-negative kidney transplantation (KT) followed by 8 weeks of glecaprevir/pibrentasvir (G/P) initiated 2 to 5 days post-KT
Number of subjects: 63

Group type: COMPARATOR
Intervention: Matched waitlist comparators who did not opt-in to receive a kidney from an HCV-viremic donor
Number of subjects: 63
Study: 35155982

Group type: EXPERIMENTAL
Intervention: SC+EP (standard care + enhanced program)
Number of subjects: 205

Group type: COMPARATOR
Intervention: SC (standard care)
Number of subjects: 205
Study: 35155984

Group type: EXPERIMENTAL
Intervention: LARGE-PACKAGE
Number of subjects: 30

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 30
Study: 35155983

Group type: EXPERIMENTAL
Intervention: Aflatoxin exposure in pregnant women in Malawi
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aflatoxin exposure in pregnant women in Bangladesh
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age 18-24 months
Number of subjects: 0
Study: 35156036

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm A)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm B)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg daily (arm C)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Osimertinib dose escalation to 160 mg
Number of subjects: 48
Study: 35156068

Group type: EXPERIMENTAL
Intervention: GX-19 (1.5 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GX-19 (3.0 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GX-19N (3.0 mg)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: GX-19N
Number of subjects: 61
Study: 35156190

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine with/without azithromycin
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Prediction maps and reference charts
Number of subjects: 476
Study: 35156195

Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat dosing of liso-cel
Number of subjects: 0
Study: 35156421

Group type: EXPERIMENTAL
Intervention: Heart transplantation candidates with mechanical circulatory support (MCS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Heart transplantation candidates without mechanical circulatory support (MCS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Candidates ineligible for heart transplantation and scheduled for long-term mechanical circulatory support (MCS)
Number of subjects: 3
Study: 35156451

Group type: EXPERIMENTAL
Intervention: Tack-Optimized Balloon Angioplasty using the Tack Endovascular System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35156500

Group type: EXPERIMENTAL
Intervention: Coach-guided videoconferencing acceptance and commitment therapy (ACT) with psychoeducation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 35156519

Group type: EXPERIMENTAL
Intervention: Targeted therapy with autophagy inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard targeted therapy without autophagy inhibition
Number of subjects: 0
Study: 35156709

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*13:02
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:02
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Anti-spike antibody titres
Number of subjects: 1364
Study: 35157306

Group type: EXPERIMENTAL
Intervention: Ofatumumab plus HyperCVAD/HD-MA (O-HyperCVAD)
Number of subjects: 37
Study: 35157313

Group type: EXPERIMENTAL
Intervention: Alopecia areata (AA)
Number of subjects: 5435
Study: 35157371

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Anifrolumab 150 mg
Number of subjects: 305
Study: 35157505

Group type: EXPERIMENTAL
Intervention: Dexcom G7 Continuous Glucose Monitoring
Number of subjects: 0
Study: 35157764

Group type: EXPERIMENTAL
Intervention: ONC201
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ONC206
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination treatment of ONC201 and ONC206
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both ONC201 and ONC206
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imipridone treatment
Number of subjects: 20
Study: 35157769

Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine (RZV) in treatment naïve (TN) CLL patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant zoster vaccine (RZV) in patients receiving BTKi therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concordant positive humoral and cellular immune response in subjects with a humoral response
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concordant positive humoral and cellular immune response in subjects without a humoral response
Number of subjects: 0
Study: 35157978

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 28 days) with Cetuximab and Radiotherapy
Number of subjects: 9
Study: 35157988

Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) models using random survival forest (RSF) method
Number of subjects: 14842

Group type: COMPARATOR
Intervention: Traditional regression models
Number of subjects: 14842
Study: 35158473

Group type: EXPERIMENTAL
Intervention: peginterferon beta-1a (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No PBH conversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NEDA achievement
Number of subjects: 0
Study: 35158476

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg over 2 years
Number of subjects: 482
Study: 35158924

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy with mEHT
Number of subjects: 210

Group type: COMPARATOR
Intervention: Chemoradiotherapy without mEHT
Number of subjects: 210
Study: 35159082

Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT) + Docetaxel
Number of subjects: 250

Group type: COMPARATOR
Intervention: Androgen-deprivation therapy (ADT) - Docetaxel
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both ADT + Docetaxel and ADT - Docetaxel
Number of subjects: 250
Study: 35159091

Group type: EXPERIMENTAL
Intervention: Oncogenic alterations in histologically negative lymph nodes
Number of subjects: 0
Study: 35160005

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels assessed during the first 24 hours of hospitalization
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Monitoring of long-term outcomes after 1 year
Number of subjects: 569
Study: 35160097

Group type: EXPERIMENTAL
Intervention: Schmitz-Hinkelbein method
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cologne method
Number of subjects: 15
Study: 35162152

Group type: EXPERIMENTAL
Intervention: Energy intake (1939.1 kcal, 95% CI: 1926.9; 1951.3)
Number of subjects: 5994

Group type: EXPERIMENTAL
Intervention: Energy expenditure (1915.7 kcal, 95% CI: 1906.4; 1924.9)
Number of subjects: 5994

Group type: EXPERIMENTAL
Intervention: Energy imbalance gap (23.4 kcal, 95% CI: 11.9; 35.0)
Number of subjects: 5994

Group type: COMPARATOR
Intervention: Energy imbalance gap in overweight and obese subjects from Argentina, Costa Rica, Ecuador, Peru, and Venezuela
Number of subjects: 5994
Study: 35162298

Group type: EXPERIMENTAL
Intervention: Open Reduction with Internal Fixation (ORIF) of acetabular fractures
Number of subjects: 31
Study: 35162337

Group type: EXPERIMENTAL
Intervention: Personal values and life satisfaction assessment
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 953
Study: 35162379

Group type: EXPERIMENTAL
Intervention: B-SWELL program
Number of subjects: 0
Study: 35162707

Group type: EXPERIMENTAL
Intervention: Symptoms of depression during lockdown
Number of subjects: 534
Study: 35162786

Group type: EXPERIMENTAL
Intervention: Self-determination enhancement group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Self-determination enhancement PLUS group (with caregivers in a parallel group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Leisure activity group
Number of subjects: 120
Study: 35162812

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 52
Study: 35162827

Group type: EXPERIMENTAL
Intervention: ReStoreD intervention (8-week remotely administered dyadic intervention)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Baseline depressive symptoms
Number of subjects: 34
Study: 35164584

Group type: EXPERIMENTAL
Intervention: Patients' willingness to deprescribe if their physician agreed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surrogates' belief in the necessity of all medications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surrogates' attribution of cost as a factor in deprescribing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients' perception of medication burden
Number of subjects: 0
Study: 35164682

Group type: EXPERIMENTAL
Intervention: Emergent endoscopic hemostasis
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Nomogram prediction model
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Decision-curve analyses and clinical impact curve
Number of subjects: 386
Study: 35164745

Group type: EXPERIMENTAL
Intervention: Cardiometabolic diseases (CMD) group
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Statins, ACE-I, ARBs, diabetes medications
Number of subjects: 791

Group type: COMPARATOR
Intervention: Absence of treatment
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: WHO (Five) Well-Being Index (WHO-5)
Number of subjects: 791
Study: 35164804

Group type: EXPERIMENTAL
Intervention: Innovative care cohort (combined somatic and mental health expertise)
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Standard care cohort (somatic expertise only)
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Innovative care cohort
Number of subjects: 1364
Study: 35164860

Group type: EXPERIMENTAL
Intervention: Aβ-positive cognitively normal (CN+) group
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Combination of plasma Aβ and gut microbiota
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Targeting the gut microbiota
Number of subjects: 88
Study: 35164933

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 25567

Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (Control)
Number of subjects: 25567
Study: 35164991

Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine
Number of subjects: 15294

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15294
Study: 35165100

Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (not treated with sunitinib)
Number of subjects: 5
Study: 35165103

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) at baseline and at the end of the first cycle of chemotherapy.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Baseline TOI ≤54
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Baseline LCS ≤21
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Early changes in LCS and baseline LCS scores
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Higher pretreatment HRQoL scores
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Declining HRQoL values
Number of subjects: 243
Study: 35165110

Group type: EXPERIMENTAL
Intervention: Macro-scale estimators (17 health-related, socioeconomic, climatic, and political factors)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Best subsets regression
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Regression analysis for tuberculosis deaths
Number of subjects: 170
Study: 35165236

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (knowledge translation intervention)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 25
Study: 35165421

Group type: EXPERIMENTAL
Intervention: Updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Number of subjects: 0
Study: 35165764

Group type: EXPERIMENTAL
Intervention: Penpulimab intravenous infusion of 1, 3 and 10 mg/kg every 2 weeks in dose-escalation phase and 200 mg every 2 weeks in dose-expansion phase (Phase Ia/Ib trial in Australia).
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Penpulimab 200 mg every 2 weeks (Phase Ib/II trial in China).
Number of subjects: 67
Study: 35166043

Group type: EXPERIMENTAL
Intervention: Microwave ablation via flexible catheter
Number of subjects: 13
Study: 35166065

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Enasidenib 100 mg once daily
Number of subjects: 151
Study: 35166465

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg IV Q2W plus axitinib
Number of subjects: 488

Group type: COMPARATOR
Intervention: Weight-based dosing of avelumab (10 mg/kg IV Q2W)
Number of subjects: 488
Study: 35166713

Group type: EXPERIMENTAL
Intervention: IMMray PanCan-d test
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: IMMray PanCan-d test (after excluding probable Lewis-null individuals)
Number of subjects: 586
Study: 35166723

Group type: EXPERIMENTAL
Intervention: NAFLD patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: HC
Number of subjects: 15
Study: 35166929

Group type: EXPERIMENTAL
Intervention: Surufatinib 250 mg QD plus toripalimab 240 mg Q3W
Number of subjects: 30
Study: 35167031

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole 300 mg twice on day 1, then 300 mg once daily on days 2-10, and either 300 mg once daily or oral suspension 200 mg 3 times daily for up to 18 days for a maximum of 28 days.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (intensive PK group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intravenous posaconazole (sparse PK group)
Number of subjects: 70
Study: 35167051

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) as an add-on to metformin for 18 months
Number of subjects: 135
Study: 35167136

Group type: EXPERIMENTAL
Intervention: Enhanced peri-operative care pathway (high-risk surgical bundle)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1189
Study: 35167187

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg twice daily
Number of subjects: 331

Group type: COMPARATOR
Intervention: Prednisone on a tapering schedule
Number of subjects: 331
Study: 35167312

Group type: EXPERIMENTAL
Intervention: High childhood trauma (Early Trauma Inventory Self Report-Short Form ≥10)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Low childhood trauma (Early Trauma Inventory Self Report-Short Form <10)
Number of subjects: 320
Study: 35167329

Group type: EXPERIMENTAL
Intervention: Adagrasib 600 mg twice a day
Number of subjects: 25
Study: 35167586

Group type: EXPERIMENTAL
Intervention: PWUD with TB disease who smoke illicit drugs
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: PWUD with microbiologic evidence of TB disease
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: PWUD
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Active TB cases among PWUD
Number of subjects: 750
Study: 35167655

Group type: EXPERIMENTAL
Intervention: tisagenlecleucel
Number of subjects: 12
Study: 35167866

Group type: EXPERIMENTAL
Intervention: Fecal signature Sa∪Sc
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Fecal signature Sa
Number of subjects: 1043

Group type: EXPERIMENTAL
Intervention: Fecal signature Sc
Number of subjects: 1043
Study: 35167907

Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE) in children treated with anthracyclines
Number of subjects: 196

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 196
Study: 35167972

Group type: EXPERIMENTAL
Intervention: Drug-free remission at 5 years
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Symptom duration
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: HAQ-AS score
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: ASDAS score
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: ASAS-NSAID score
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Anti-TNF use
Number of subjects: 412
Study: 35167984

Group type: EXPERIMENTAL
Intervention: Q-LSI[4m] >59%
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: H-LSI[4m] >72%
Number of subjects: 113
Study: 35168241

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Laparotomic myomectomy
Number of subjects: 62
Study: 35168380

Group type: EXPERIMENTAL
Intervention: Social resources provided during discharge support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35168547

Group type: EXPERIMENTAL
Intervention: Rituximab 1000 mg on days -14 and -7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab every 6 months thereafter (Protocol 1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 concomitantly with gemcitabine/cisplatin (Protocol 2)
Number of subjects: 10
Study: 35168565

Group type: EXPERIMENTAL
Intervention: Scheduled asthma contacts in primary health care (PHC)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Scheduled asthma contacts in secondary care
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Heavy alcohol consumption
Number of subjects: 203
Study: 35168605

Group type: EXPERIMENTAL
Intervention: Asprosin treatment in HUVECs
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Circulating asprosin levels in DM + PAD group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Asprosin as a diagnostic marker
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Metabolomics data
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: TGF-β signaling pathway
Number of subjects: 114
Study: 35168661

Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI) integrated into youth entrepreneurship programs (ENTR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative team approach (CTA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth entrepreneurship and livelihood programs
Number of subjects: 0
Study: 35168844

Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin (EV)
Number of subjects: 125
Study: 35168985

Group type: EXPERIMENTAL
Intervention: Inertial sensor technology for sensorimotor control assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Regular physical activity levels
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Symptoms related to central sensitisation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Usability of the inertial measurement unit sensor technology
Number of subjects: 104
Study: 35168986

Group type: EXPERIMENTAL
Intervention: 75-g five-point oral glucose tolerance test (OGTT) during and after pregnancy
Number of subjects: 800
Study: 35168989

Group type: EXPERIMENTAL
Intervention: ICTAL Registry observational methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core data set from ICTAL Registry
Number of subjects: 0
Study: 35169140

Group type: EXPERIMENTAL
Intervention: Treated with prednisone and/or antibiotics in the outpatient setting
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treated in an urgent care or ED setting
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hospitalized
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 60
Study: 35169170

Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) measured on admission
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Physiological data recording and HRV parameters (LF/HF and Shannon entropy)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Machine-learning using neural network (kNN)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: HRV measured on admission
Number of subjects: 540
Study: 35169806

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study: 35169968

Group type: EXPERIMENTAL
Intervention: Masimo O3™ regional cerebral oxygen saturation (rSO2) monitoring
Number of subjects: 0